Subcutaneously administered Menopur(R), a new highly purified human menopausal gonadotropin,causes significantly fewer injection site reactions than Repronex(R) in subjects undergoing in vitro fertilization期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Subcutaneously administered Menopur(R), a new highly purified human menopausal gonadotropin,causes significantly fewer injection site reactions than Repronex(R) in subjects undergoing in vitro fertilization

Authors:	William?R?Keye Bobby?Webster Richard?Dickey Stephen?Somkuti Jack?Crain Email author" target="_blank">M?Joseph?Scobey Email author

Institution:	(1) William Beaumont Hospital, In Vitro Fertility Clinic, Royal Oak, Michigan, USA;(2) Woman's Center for Fertility, Baton Rouge, Louisiana, USA;(3) Fertility Institute of New Orleans, New Orleans, Louisiana, USA;(4) Abington Reproductive Medicine, Abington, Pennsylvania, USA;(5) Reproductive Endocrine Associates of Charlotte, Charlotte North Carolina, USA;(6) Ferring Pharmaceuticals Inc., Suffern, New York, USA

Abstract:	Background The safety and tolerability of a new highly purified, urine-derived human menopausal gonadotropin (hMG) preparation Menopur(R)] was compared with a currently available hMG Repronex (R)] in women undergoing in vitro fertilization (IVF).

Keywords:
本文献已被 SpringerLink 等数据库收录！